Table 8. References for studies on cisplatin–based chemoradiotherapy regimen (continued).
| CIS-CRT | Study | LRC | DC | Response | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Arms | 2-yr LRC | Diff in LRC | 3-yr DC | 5-yr DC | Diff in DC | Overall resp | Diff in resp | |||||
| HDC vs. RT | Pignon et al. (1) | CRT vs. LRT | CRT improves LRC, P=0.04 | ICT improves DC, P=0.001 | – | – | |||||||
| ICT vs. LRT | – | – | |||||||||||
| Adelstein et al. (2) | A. RT alone | – | – | – | – | – | 27.4% (CR) | C>A, P=0.002; A vs. B, P=0.07 | |||||
| B. CRT | – | – | – | – | – | 40.2% (CR) | |||||||
| C. Split CRT | – | – | – | – | – | 49.4% (CR) | |||||||
| Cooper et al. (5) | A. RT alone | 72% | B>C, P=0.01 | 77%, ns | P=0.46 | – | – | ||||||
| B. CRT | 82% | 80%, ns | – | – | |||||||||
| Bernier et al. (6) | A. RT alone | 69%, 5-yr LRC | B>A, P=0.007 | – | 75% | P=0.61 | – | – | |||||
| B. CRT | 88%, 5-yr LRC | – | 79% | – | – | ||||||||
| LDC vs. RT | Bachaud et al. (9) | A. RT alone | 59% | B>A, P=0.05 | 81% (2-yr) | 49% | None reported | – | – | ||||
| B. CRT | 84% | 73% (2-yr) | 58% | – | – | ||||||||
| Sharma et al. (10) | A. RT alone | 53%, overall | P=0.26 | 97%, overall | – | P=0.05 | 67% (CR) | B>A, P=0.04 | |||||
| B. CRT | 66%, overall | 90%, overall | – | 81% (CR) | |||||||||
| Ghosh-Laskar et al. (11) |
A. RT alone | 32%, 5-yr LRC | B>A, P=0.01 | – | – | None reported | – | – | |||||
| B. CRT | 49%, 5-yr LRC | – | – | – | – | ||||||||
| HDC vs. LDC | Lee et al. (12) | A. HDC-CRT | – | – | – | – | – | 92% | P=0.81 | ||||
| B. LDC-CRT | – | – | – | – | – | 91% | |||||||
| Helfenstein et al. (13) | A. HDC-CRT | – | – | – | – | – | – | – | |||||
| B. LDC-CRT | – | – | – | – | – | – | – | ||||||
| Bauml et al. (14) | A. HDC-CRT | – | – | – | – | – | – | – | |||||
| B. LDC-CRT | – | – | – | – | – | – | – | ||||||
| Szturz et al. (15) | A. HDC-CRT | Unable to merge data | Unable to merge data | 80.0% | No diff | ||||||||
| B. LDC-CRT | 89.0% | ||||||||||||
| Tsan et al. (16) | A. HDC-CRT | 71% (1-yr) | P=0.81 | – | – | – | – | – | |||||
| B. LDC-CRT | 60% (1-yr) | – | – | – | – | – | |||||||
| Noronha et al. (17) | A. HDC-CRT | 73% | A>B, P=0.014 | – | – | – | – | – | |||||
| B. LDC-CRT | 59% | – | – | – | – | – | |||||||
Cis, cisplatin; CRT, chemoradiation; LRC, locoregional control; DC, distant control; Diff, difference; Resp, response; HDC, high dose cisplatin (80–100 mg/m2 3-weekly, 2–3 cycles); LDC, low dose cisplatin (30–50 mg/m2 weekly, 6–9 cycles); RT, radiotherapy; LRT, locoregional treatment; CR, complete response; ns, not specified.